Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size and Its Estimated Growth Rate?
The market for nucleic acid and gene therapies in neuromuscular disorders has experienced robust growth recently. The market, which is projected to rise from $6.84 billion in 2024 to $7.52 billion in 2025, boasts a compound annual growth rate (CAGR) of 9.9%. This historical growth is largely due to a rise in regulatory approvals, the popularity of nucleic acid therapeutics, the need for more accurate and potent treatments, the demand for efficient gene therapies, and an increase in the discovery of gene therapy-based treatments.

The market for nucleic acid and gene therapies focused on neuromuscular disorders is anticipated to experience robust expansion in the upcoming years, rising to a worth of $10.87 billion in 2029 with a compound annual growth rate (CAGR) of 9.7%. This growth during the projected period can be ascribed to the rising cases of genetic disorders, escalated investment in research and development, increasing demand for individualized medicine, an uptick in the approval of gene therapy products, and a surge in chronic disease prevalence. Notable trends during this forecast period encompasses improvements in patient care, the rise of high-performance chromatography, innovative solutions for various conditions, evolution in gene editing technologies, and the wider availability of nucleic acid extraction technology.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21233

How Are Emerging Segments Shaping the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Landscape?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented -

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy
3) By Application: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp

Which Growth Factors Are Influencing Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Expansion?
The surge in genetic disorders is anticipated to drive the growth of the nucleic acid and gene therapies market in the context of neuromuscular disorders. These disorders stem from irregularities in a person's DNA, which can either be inherited or occur as a result of genetic mutations. Several factors, including genetic mutations, the environment, lifestyle changes, and better diagnostic mechanisms are responsible for the rise in genetic disorders. Defective genes in neuromuscular conditions can be corrected or replaced using nucleic acid and gene therapies, thereby restoring their normal operations. For example, a non-profit organization in the US known as Cure SMA reported in May 2024 that between 9,000 and 9,500 people are currently battling Spinal Muscular Atrophy (SMA) in the country. Out of these, 37% have Type 2 SMA. The disease has an estimated occurrence rate of 1 in every 15,000 births. Thus, the increasing prevalence of genetic disorders is pushing the nucleic acid and gene therapies market in neuromuscular disorders towards growth.

Who Are the Dominant Players Across Different Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segments?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.

What Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends Are Gaining Traction Across Different Segments?
Leading corporations are engaged in the neuromuscular disorders' nucleic acid and gene therapies market, concentrating on the creation of revolutionary treatments such as gene therapy. This method aims to tackle the fundamental issues of genetic neuromuscular disorders through specific gene correction or substitution. Gene therapy involves curing diseases by introducing, modifying, or restoring genetic material within a patient's cells to correct or supplement defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a prominent biotechnology firm based in the US, gained approval from the U.S. Food and Drug Administration for Elevidys - the pioneering gene therapy for Duchenne Muscular Dystrophy, particularly for ambulant pediatric patients aged between 4 and 5 years. The therapy is delivered as a sole intravenous infusion, making the treatment procedure simpler than other treatments that may necessitate continuous infusions. ELEVIDYS provides a gene coding for a truncated form of dystrophin, referred to as micro-dystrophin, indispensable for muscle function. This innovative methodology tackles the root genetic flaw by facilitating muscle cells to generate a functional version of the dystrophin protein, possibly stopping or reversing disease progression.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Which Geographic Regions Are Expected to Dominate the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market in the Coming Years?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
2. What is the CAGR expected in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
3. What Are the Key Innovations Transforming the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry?
4. Which Region Is Leading the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.